CoChat

Chlamydia pneumoniae Infection and Risk for Lung Cancer

Open access
Chaturvedi, Anil K., Gaydos, Charlotte A., Agreda, Patricia, Holden, Jeffrey P., Chatterjee, Nilanjan, Goedert, James J., Caporaso, Neil E., Engels, Eric A. · 2010 · Cancer Epidemiology, Biomarkers & Prevention

Published version of a preprint

Cited by 150

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Background: We evaluated the relationship of Chlamydia pneumoniae infection with prospective lung cancer risk using traditional serologic markers [microimmunoflourescence (MIF) IgG and IgA antibodies] and Chlamydia heat shock protein-60 (CHSP-60) antibodies, a marker for chronic chlamydial infection. Methods: We conducted a nested case-control study (593 lung cancers and 671 controls) within the screening arm of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (N = 77,464). Controls were matched to cases by age, sex, randomization year, follow-up time, and smoking (pack-years of smoking, time since quitting). We assessed C. pneumoniae seropositivity and endpoint antibody titers (IgG and IgA against C. pneumoniae elementary bodies and IgG against CHSP-60). Results: C. pneumoniae seropositivity by microimmunoflourescence IgG or IgA antibodies was not associated with lung cancer [odds ratio of 0.88 and 95% confidence interval (95% CI) of 0.69-1.13 for IgG; odds ratio of 0.98 and 95% CI of 0.75-1.27 for IgA]. In contrast, individuals seropositive for CHSP-60 IgG antibodies had significantly increased lung cancer risk (odds ratio, 1.30; 95% CI, 1.02-1.67), and risk increased with increasing antibody titers (P trend = 0.006). CHSP-60–related risk did not differ significantly by lung cancer histology, follow-up time, or smoking. CHSP-60 seropositivity was associated with increased risk 2 to 5 years before lung cancer diagnosis (odds ratio, 1.77; 95% CI, 1.16-2.71; P trend = 0.006), thus arguing against reverse causality. Conclusions: CHSP-60 seropositivity and elevated antibody titers were associated with significantly increased risk for subsequent lung cancer, supporting an etiologic role for C. pneumoniae infection in lung carcinogenesis. Impact: Our results highlight the potential for lung cancer risk reduction through treatments targeted toward C. pneumoniae infections and chronic pulmonary inflammation. Cancer Epidemiol Biomarkers Prev; 19(6); 1498–505. ©2010 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1055-9965.epi-09-1261

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 33

  1. Alberg, 2005, Epidemiology of lung cancer: looking to the future, J Clin Oncol, 23, 3175, 10.1200/JCO.2005.10.462 · DOI · Paper page
  2. Parkin, 2005, Global cancer statistics, 2002, CA Cancer J Clin, 55, 74, 10.3322/canjclin.55.2.74 · DOI · Paper page
  3. Sun, 2007, Lung cancer in never smokers—a different disease, Nat Rev Cancer, 7, 778, 10.1038/nrc2190 · DOI · Paper page
  4. Engels, 2008, Inflammation in the development of lung cancer: epidemiological evidence, Expert Rev Anticancer Ther, 8, 605, 10.1586/14737140.8.4.605 · DOI · Paper page
  5. Ballaz, 2003, The potential contributions of chronic inflammation to lung carcinogenesis, Clin Lung Cancer, 5, 46, 10.3816/CLC.2003.n.021 · DOI · Paper page
  6. Hahn, 2002, Chlamydia pneumoniae as a respiratory pathogen, Front Biosci, 7, e66, 10.2741/hahn · DOI
  7. Laurila, 1997, Serological evidence of an association between Chlamydia pneumoniae infection and lung cancer, Int J Cancer, 74, 31, 10.1002/(SICI)1097-0215(19970220)74:1<31::AID-IJC6>3.0.CO;2-1 · DOI · Paper page
  8. Jackson, 2000, Association of Chlamydia pneumoniae immunoglobulin A seropositivity and risk of lung cancer, Cancer Epidemiol Biomarkers Prev, 9, 1263
  9. Littman, 2004, Chlamydia pneumoniae infection and risk of lung cancer, Cancer Epidemiol Biomarkers Prev, 13, 1624, 10.1158/1055-9965.1624.13.10 · DOI · Paper page
  10. Littman, 2005, Chlamydia pneumoniae and lung cancer: epidemiologic evidence, Cancer Epidemiol Biomarkers Prev, 14, 773, 10.1158/1055-9965.EPI-04-0599 · DOI · Paper page
  11. Kocazeybek, 2003, Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study, J Med Microbiol, 52, 721, 10.1099/jmm.0.04845-0 · DOI
  12. Smith, 2008, Lack of association between serum antibodies of Chlamydia pneumoniae infection and the risk of lung cancer, Int J Cancer, 123, 2469, 10.1002/ijc.23814 · DOI
  13. Koh, 2005, Lack of association between chronic Chlamydophila pneumoniae infection and lung cancer among nonsmoking Chinese women in Singapore, Int J Cancer, 114, 502, 10.1002/ijc.20745 · DOI
  14. Littman, 2004, Interlaboratory reliability of microimmunofluorescence test for measurement of Chlamydia pneumoniae-specific immunoglobulin A and G antibody titers, Clin Diagn Lab Immunol, 11, 615
  15. Dowell, 2001, Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada), Clin Infect Dis, 33, 492, 10.1086/322632 · DOI · Paper page
  16. Peeling, 1999, Heat shock protein expression and immunity in chlamydial infections, Infect Dis Obstet Gynecol, 7, 72, 10.1155/S1064744999000149 · doi:10.1155/s1064744999000149
  17. Stephens, 2003, The cellular paradigm of chlamydial pathogenesis, Trends Microbiol, 11, 44, 10.1016/S0966-842X(02)00011-2 · DOI · Paper page
  18. Peeling, 1998, Antibody response to the 60-kDa chlamydial heat-shock protein is associated with scarring trachoma, J Infect Dis, 177, 256, 10.1086/517367 · doi:10.1086/517367
  19. Peeling, 1999, Antibody response to the chlamydial heat-shock protein 60 in an experimental model of chronic pelvic inflammatory disease in monkeys (Macaca nemestrina), J Infect Dis, 180, 774, 10.1086/314919 · doi:10.1086/314919
  20. Eckert, 1997, Prevalence and correlates of antibody to chlamydial heat shock protein in women attending sexually transmitted disease clinics and women with confirmed pelvic inflammatory disease, J Infect Dis, 175, 1453, 10.1086/516479 · doi:10.1086/516479
  21. Bax, 2004, Chlamydia trachomatis heat shock protein 60 (cHSP60) antibodies in women without and with tubal pathology using a new commercially available assay, Sex Transm Infect, 80, 415, 10.1136/sti.2004.009167 · DOI
  22. Tiitinen, 2006, Chlamydia trachomatis and chlamydial heat shock protein 60-specific antibody and cell-mediated responses predict tubal factor infertility, Hum Reprod, 21, 1533, 10.1093/humrep/del014 · doi:10.1093/humrep/del014
  23. Mahdi, 2002, Serum immunoglobulin G antibodies to chlamydial heat shock protein 60 but not to human and bacterial homologs are associated with coronary artery disease, Circulation, 106, 1659, 10.1161/01.CIR.0000031567.10814.D8 · DOI
  24. Biasucci, 2003, Antibody response to chlamydial heat shock protein 60 is strongly associated with acute coronary syndromes, Circulation, 107, 3015, 10.1161/01.CIR.0000078632.76653.6C · DOI
  25. Prorok, 2000, Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, Control Clin Trials, 21, 273, 10.1016/S0197-2456(00)00098-2 · DOI · Paper page
  26. Hayes, 2005, Methods for etiologic and early marker investigations in the PLCO trial, Mutat Res, 592, 147, 10.1016/j.mrfmmm.2005.06.013 · DOI
  27. Wang, 1979, Formalinized Chlamydia trachomatis organisms as antigen in the micro-immunofluorescence test, J Clin Microbiol, 10, 259, 10.1128/jcm.10.2.259-261.1979 · doi:10.1128/jcm.10.2.259-261.1979
  28. Suzuki, 2006, Serum heat shock protein 70 levels and lung cancer risk: a case-control study nested in a large cohort study, Cancer Epidemiol Biomarkers Prev, 15, 1733, 10.1158/1055-9965.EPI-06-0005 · DOI
  29. Chaturvedi, C-reactive protein and risk of lung cancer, J Clin Oncol
  30. Siscovick, 2000, Collaborative multidisciplinary workshop report: the role of epidemiology studies in determining a possible relationship between Chlamydia pneumoniae infection and atherothrombotic diseases, J Infect Dis, 181, S430, 10.1086/315598 · doi:10.1086/315598
  31. Siscovick, 2000, Chlamydia pneumoniae and atherosclerotic risk in populations: the role of seroepidemiology, J Infect Dis, 181, S417, 10.1086/315623 · DOI
  32. Fong, 2002, Chlamydial heat-shock protein-60 antibody and correlation with Chlamydia pneumoniae in atherosclerotic plaques, J Infect Dis, 186, 1469, 10.1086/344730 · DOI
  33. Koyi, 2001, An association between chronic infection with Chlamydia pneumoniae and lung cancer. A prospective 2-year study, APMIS, 109, 572, 10.1034/j.1600-0463.2001.d01-177.x · DOI · Paper page

Cited by

See all 150

Metadata

Authors
Chaturvedi, A. K., Gaydos, C. A., Agreda, P., Holden, J. P., Chatterjee, N., Goedert, J. J., Caporaso, N. E., & Engels, E. A.
Venue
Cancer Epidemiology, Biomarkers & Prevention
Published
2010-06-01
Volume
19
Issue
6
Pages
1498-1505
ISSN
  • 1055-9965 (ISSN-L)
  • 1538-7755
OpenAlex
W2128959177
Cited by
150
References
2
FWCI
6.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chlamydia pneumoniae Infection and Risk for Lung Cancer. https://app.cochat.ai/papers/10.1158/1055-9965.epi-09-1261
The paper
Chaturvedi, A. K., Gaydos, C. A., Agreda, P., Holden, J. P., Chatterjee, N., Goedert, J. J., Caporaso, N. E., & Engels, E. A. (2010). Chlamydia pneumoniae Infection and Risk for Lung Cancer. Cancer Epidemiology, Biomarkers & Prevention. https://doi.org/10.1158/1055-9965.epi-09-1261

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.